观察调贲降逆颗粒联合艾司奥美拉唑镁肠溶胶囊治疗胃食管反流性咳嗽（GERC）胃气上逆证的效果。

收集2022年1月至2023年6月新疆维吾尔自治区人民医院消化科、呼吸科、耳鼻喉科、中医科住院部及门诊就诊GERC患者且中医辨证属胃气上逆型的40例患者进行随机对照前瞻性研究。随机分为对照组（20例）和治疗组（20例）。对照组患者单纯给予艾司奥美拉唑镁肠溶胶囊，治疗组患者给予调贲降逆颗粒联合艾司奥美拉唑镁肠溶胶囊，疗程均为4周。使用简易咳嗽程度评分表（CET）评估2组治疗前后GERC咳嗽严重程度，采用GERD-Q量表评定胃食管反流情况，并对中医症状、复发率、安全性进行评定。

2组患者治疗前CET评分、GERD-Q量表积分、中医症候评分比较，差异均无统计学意义（P>0.05）。治疗4周后，治疗组患者CET评分明显低于对照组，差异有统计学意义[（9.70±1.81）比（11.15±2.16）分，P<0.05]；治疗组患者GERD-Q量表评分明显低于对照组，差异有统计学意义[（4.60±1.43）比（6.60±2.01）分，P<0.05]；治疗组患者中医症状积分明显低于对照组，差异有统计学意义（P<0.05）。治疗组的复发率为10%，对照组的复发率为40%，治疗组复发率明显低于对照组（P<0.05）。

与艾司奥美拉唑镁肠溶胶囊单用相比，调贲降逆颗粒联合艾司奥美拉唑镁肠溶胶囊对GERC胃气上逆证具有更好的治疗作用。

To observe the effect of Tiaobenjiangi Granule combined with Esomeprazole magnesium enteric-coated capsule in the treatment of gastroesophageal reflux cough (GERC).

From January 2022 to June 2023, 40 patients with GERC in the Gastroenterology, respiratory, otolaryngology, inpatient department of Traditional Chinese Medicine and outpatient department of the People's Hospital of Xinjiang Uygur Autonomous Region were collected for a randomized controlled prospective study. They were randomly divided into control group (20 cases) and treatment group (20 cases). The control group was given esomeprazole magnesium enteric-coated capsule alone, and the treatment group was given Tiaobingjiangi granules combined with esomeprazole magnesium enteric-coated capsule, the course of treatment was 4 weeks. The severity of GERC cough before and after treatment was assessed using the Cough Evaluation Test(CET), the GERD-Q scale was used to evaluate the gastroesophageal reflux, and the TCM symptoms, recurrence rate and safety were evaluated.

There was no significant difference in CET score, Gerd Q scale score and TCM symptom score between 2 groups before treatment (P>0.05). After 4 weeks of treatment, CET score in the treatment group was significantly lower than that in the control group, with statistical significance [(9.70±1.81) vs. (11.15±2.16) points, P<0.05]. The Gerd Q scale score of the treatment group was significantly lower than that of the control group, and the difference was statistically significant [(4.60±1.43) vs. (6.60±2.01) points, P<0.05]. The scores of TCM symptoms in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). The recurrence rate was 10% in the treatment group and 40% in the control group, and the recurrence rate in the treatment group was significantly lower than that in the control group (P<0.05).There were no statistically significant differences in CET score, GERD-Q scale score and TCM symptoms between the two groups before treatment (P>0.05). In terms of improvement of gastroesophageal reflux symptoms, the treatment group was significantly better than the control group, and the differences were statistically significant (P<0.05). The treatment group was significantly better than the control group (P<0.05). The relief of cough, expectoration, acid reflux and belching in the treatment group was significantly better than that in the control group (P<0.05). The recurrence rate in the treatment group was 10%, and the effective rate in the control group was 40%, which was significantly lower in the treatment group than that in the control group (P<0.05).

Compared with esomeprazole magnesium enteric-coated capsule alone, Tiaobenjiangi granule combined with esomeprazole magnesium enteric-coated capsule had a better therapeutic effect on the gastric qi inversion syndrome of GERC.